|
|
Volumn 351, Issue , 2015, Pages h6122-
|
|
21st Century Cures Act and similar policy efforts: at what cost?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NEW DRUG;
NOOTROPIC AGENT;
ALZHEIMER DISEASE;
CLINICAL TRIAL (TOPIC);
DRUG SCREENING;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
GOVERNMENT REGULATION;
HEALTH CARE POLICY;
HUMAN;
LEGISLATION AND JURISPRUDENCE;
OUTCOME ASSESSMENT;
PROCEDURES;
STANDARDS;
TRENDS;
UNITED STATES;
ALZHEIMER DISEASE;
CLINICAL TRIALS AS TOPIC;
DRUG EVALUATION;
DRUGS, INVESTIGATIONAL;
GOVERNMENT REGULATION;
HEALTH POLICY;
HUMANS;
NOOTROPIC AGENTS;
PATIENT OUTCOME ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84991229701
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.h6122 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|